Diagnosing COVID Via a Smartphone App
ResApp Health (ASX: RAP) is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.
Read MoreBiotechnology
Immutep Taking the Fight to Cancer
Following on from his previous report on the company, Corporate Connect analyst Marc Sinatra has today published an updated analysis of ASX-listed biotech Immutep Ltd (ASX: IMM), valuing IMM at $A2.20 per share.
Read MoreAntisense Duchenne’s Trial Set for Approval?
Corporate Connect analyst Marc Sinatra has released an update of his previous research report on Antisense Therapeutics, placing a 12-month price target on the company of $A0.48.
Read MoreThe Three Drivers of Innovation in Biotech Stocks
In this video, John Hall from T. Rowe Price looks at the three drivers of innovation in the biotech industry that are creating investment opportunities that will help shape the future of medicine.
Read MoreImmutep Leading the development of immunotherapy for cancer and autoimmune diseases
Pengana Fund manager James McDonald provides insight into why he believes biotech Immutep is very well placed to benefit from the current environment and how it fits in the portfolio structure.
Read More
For a Life Free of Pain
Regenerative medicine company Regeneus is at the forefront of providing a novel, stem cell-based therapy for knee osteoarthritis which afflicts hundreds of millions of people worldwide.
Read MoreApple’s surveillance challenge, blockchain gaming capital raises, and the start of suborbital spaceflight sales
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreGenetic Signatures: Australia’s Rapid Growth Diagnostics Company
Genetic Signatures’ growth strategy is about building its customer numbers, the range of its proprietary tests for COVID-19 and a range of viral, protozoan, fungal and bacterial infections.
Read MoreMemphasys Taking on One of Humanity’s Most Pressing Issues
Humanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, leading to health problems.
Read MoreTime crystals, sodium-ion batteries, and where to go when civilisation collapses
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreThe Road Forward for Antisense
Managing Director and CEO Mark Diamond discusses the key highlights of the quarterly results for Antisense Therapeutics and other recent company news of note.
Read MoreInstitutions Support Immutep Capital Raising
Australian biotech company Immutep has announced it has completed the second tranche of its institutional placement at an issue price of A$0.52 per share to raise approximately A$46.3 million.
Read MoreOptical deep-learning, a potential grid-scale battery tipping point, and Chinese cybersecurity regulations
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreBiopharma’s Targeted Approach to Growth
Janus Henderson’s Andy Acker and Agustin Mohedas explain how a new drug targeting a common mutation found in tumours could benefit patients and biopharma alike.
Read MoreCancer vaccines, streaming market share, and the $1bn crypto-trading startup
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreAI-designed chips, a new self-driving competitor, and Bitcoin becomes legal tender
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreAlzheimer’s Decision Sends Positive Message to Aussie Biotechs
The US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read MoreFPH Announces 61% Profit Jump, Shares Fall 6%
Shares in New Zealand medical technology group Fisher & Paykel Healthcare took a pounding yesterday despite the company turning in a stellar result for its 2021 financial year.
Read MoreGene-edited immune cells fight cancer, robotic hands that can feel, and the first entanglement-based quantum network
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreGinkgo Comes to Market, NFTs in Gaming, and Wind Gets a Boost
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreStockholdings at Record Levels, Digital Advertising Booming, and 500 Million Gene-Hacked Mosquitoes Unleashed
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreApple held hostage, Amazon hair salons, and the rise and role of meme stocks
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreCoinbase Cryptomania, LOTR’s Pricey Production, and Google’s Timelapse of Earth
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreKazia Licenses New Oncology Drug Candidate
Kazia Therapeutics has announced that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE, a leading European drug discovery and development company.
Read MoreReversible CRISPR, Life-Extending Young Blood, and the Rise of Robo-Advisors
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreHow mRNA-based therapies could change the world, Biden’s renewables boost, and the semi shortage
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreSolar Geoengineering, Intel’s Strategy Update, and Breaking the Blood-Brain Barrier
Thomas Rice, portfolio manager for the Perpetual Global Innovation Share Fund provides his regular wrap of technology, innovation, and finance news.
Read MoreWhat VW Power Day Means for the Lithium Market
ShareCafe’s Tim McGowen spoke with Steve Promnitz, CEO of Lake Resources (ASX: LKE) about what VW’s announcement that it would build six new battery factories in Europe means for the lithium space.
Read MoreThe Healthcare Technologies Helping Us Out of this Pandemic
Advances in genome sequencing and in other healthcare technologies have played a critical role in controlling the COVID-19 pandemic. This article from Pengana Capital explains how.
Read MoreIndustry Expert Sees the Path Forward for Antisense Therapeutics
Australian biotechnology company Antisense Therapeutics Limited recently appointed Gil Price M.D. as a Consultant Medical Director. He spoke with with ShareCafe’s Tim McGowen about his new role.
Read MoreGenetic Signatures Leverages New Screening Targets to EU and US Markets
GeneticSignatures (ASX: GSS) a specialist molecular diagnostics (MDx) company, plans to leverage its existing suite of real-time screening products into an expanding customer base.
Read MoreKazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company
Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.
Read MoreTurnaround in Place at Cochlear
Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.
Read MoreCOVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read MoreNoxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates
Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company’s CEO Dr Graham Kelly tells us more.
Read MoreRobotics and A.I.: Defeating COVID-19
Alex Cook from BetaShares examines the role robotics and A.I. have played not only in developing a vaccine but also in its distribution.
Read MoreGrowth For ResMed Despite Challenges
Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.
Read MoreAntisense Therapeutics – Price Target Raised from $0.305 to $0.43
Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read MoreImmutep: fighting the good fight
In this video, immunotherapy pioneer Immutep’s (ASX: IMM) CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments.
Read More